Simcere Receives CFDA Approval For Anti-Rheumatic Drug Iremod

The State Food and Drug Administration has approved Simcere Pharmaceutical Group’s new anti-rheumatic drug, Iremod, used to treat symptoms of active rheumatic arthritis.

AsianScientist (Aug. 28, 2011) – Simcere Pharmaceutical Group, a company that develops, manufactures, and markets branded generic and proprietary pharmaceuticals in China, announced this Thursday that it has received new drug approval from the State Food and Drug Administration for the sale of Iremod in China.

Iremod, which was independently developed by Simcere, will be the first Iguratimod anti-rheumatic drug on the global market. It is a new drug in the category of Disease Modifying Anti-rheumatic Drugs (DMARDS), and will be primarily used in the treatment of active rheumatoid arthritis.

According to Simcere, clinical studies demonstrate that Iremod can significantly alleviate symptoms caused by active rheumatoid arthritis.

“Bringing Iremod to the Chinese market will allow millions of patients suffering from active rheumatoid arthritis to enjoy higher quality treatment. Iremod will provide new and more effective options for doctors,” said Mr. Ren Jinsheng, Chairman and Chief Executive Officer of Simcere.

“This approval is a breakthrough for Simcere. We will continue to put our efforts and resources into developing and producing effective and innovative medicines for patients,” he said.

Other products by Simcere include the anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan.

——

Source: Simcere Pharmaceutical Group.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist